Sienna Biopharmaceuticals Inc. (SNNA)’s Financial Results Comparing With Esperion Therapeutics Inc. (NASDAQ:ESPR)

We are comparing Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) and Esperion Therapeutics Inc. (NASDAQ:ESPR) on their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sienna Biopharmaceuticals Inc. N/A 0.00 73.47M -2.77 0.00
Esperion Therapeutics Inc. N/A 0.00 201.81M -6.75 0.00

Demonstrates Sienna Biopharmaceuticals Inc. and Esperion Therapeutics Inc. earnings per share, top-line revenue and valuation.


Table 2 demonstrates the return on equity, return on assets and net margins of Sienna Biopharmaceuticals Inc. and Esperion Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Sienna Biopharmaceuticals Inc. 0.00% -97.5% -50.2%
Esperion Therapeutics Inc. 0.00% -91.3% -77.2%


Sienna Biopharmaceuticals Inc.’s Current Ratio and Quick Ratio are 4.9 and 4.9 respectively. The Current Ratio and Quick Ratio of its competitor Esperion Therapeutics Inc. are 4 and 4 respectively. Sienna Biopharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Esperion Therapeutics Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Sienna Biopharmaceuticals Inc. and Esperion Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sienna Biopharmaceuticals Inc. 0 0 0 0.00
Esperion Therapeutics Inc. 1 3 4 2.50

Esperion Therapeutics Inc. on the other hand boasts of a $67.75 consensus target price and a 59.41% potential upside.

Institutional and Insider Ownership

Roughly 32.3% of Sienna Biopharmaceuticals Inc. shares are owned by institutional investors while 0% of Esperion Therapeutics Inc. are owned by institutional investors. Insiders owned 4.3% of Sienna Biopharmaceuticals Inc. shares. Competitively, Esperion Therapeutics Inc. has 2.2% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sienna Biopharmaceuticals Inc. 13.44% 7.09% -71.81% -83.09% -82.01% 23.71%
Esperion Therapeutics Inc. -1.37% -0.52% -11.78% -7.08% -39.96% 0.46%

For the past year Sienna Biopharmaceuticals Inc. has stronger performance than Esperion Therapeutics Inc.


Sienna Biopharmaceuticals Inc. beats on 5 of the 7 factors Esperion Therapeutics Inc.

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes topical products for medical dermatology and aesthetics markets in North America. The companyÂ’s lead product candidates include SNA-120, a TrkA inhibitor, which is in Phase 2b clinical development for the treatment of pruritus, itch, and neurogenic inflammation associated with psoriasis; and SNA-125, a dual JAK3/TrkA inhibitor that is in pre-clinical study for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a photoparticle therapy, which is in pivotal clinical trials for the treatment of acne vulgaris and the reduction of unwanted light-pigmented hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.